Drugs / EXE-346 Probiotic
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06949800 | Sep 2026 → May 2027 expected | human papillomavirus-related squamous cell carcinoma, squamous cell intraepithelial neoplasia | University of California, San Francisco | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EXE-346 Probiotic | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06949800 ↗ |
| Route | Oral | “consumed orally twice per day” NCT06949800 ↗ |